Press release
Partnership project between the pharmaceutical industry and the NHS recognised as an example of a 'global top 100' IT organisation
A joint venture between the pharmaceutical industry and the NHS which has developed a system to help improve the way that cancer medicines are provided to patients has been selected by CIO magazine as one of the “Top 100” global IT organisations.The IT system called C-PORT (Chemotherapy Planning Oncology Resource Tool) was developed by the Pharmaceutical Oncology Initiative Partnership (POIP), a joint venture between 12 member companies of the Association of the British Pharmaceutical Industry (ABPI), the Cancer Action Team and the Cancer Services Collaborative Improvement Partnership. The system was developed to help tackle the problem that the uptake of new cancer medicines varies widely across the UK – so called “postcode prescribing”.
The system itself is a “capacity simulator”, a sophisticated modelling tool which uses statistical methods to predict how chemotherapy units will perform under different conditions. It allows chemotherapy units to plan for the uptake of new cancer medicines and redesign the way they deliver chemotherapy to improve efficiency and patient experience.
Over 80 front line staff were consulted during the design and test programme and it is currently being rolled out across the NHS with overwhelming support from the doctors, nurses, pharmacists and managers who will use it. Professor Mike Richards, the National Cancer Director said: “I strongly recommend that Cancer Networks and their stakeholders use this tool to improve forward planning for cancer drugs.”
The tool was designed for the POIP by A.T. Kearney, a management consultancy, and built by Concentra, a UK IT provider, and ITransition, an offshore developer. Said Jonathan Anscombe, head of the A.T. Kearney health practice: “It proved to be a really complicated problem, so C-PORT pushes the boundaries of this type of simulation tool.”
“The success of the project also shows how the pharmaceutical industry can collaborate effectively with the NHS for the benefit of patients. Such collaborations have an important role to play in helping to improve health delivery,” said Dr Richard Barker, Director General of the ABPI.
For more information please contact:
CIO Magazine is one of the leading magazines for IT professionals. Every year, the CIO 100 Awards honour 100 companies that demonstrate excellence and achievement in IT. The process for choosing the CIO 100 honorees is systematic and very competitive. The prize is for companies that are using IT in innovative ways to deliver competitive advantage to the enterprise and enable growth. www.cio.com
Pharmaceutical Oncology Initiative Partnership (POIP) was set up in 2005 to identify opportunities to collaborate on projects to benefit cancer patients by improving uptake and access to cancer medicines. The partners include the Cancer Action Team, NHS Cancer Services Collaborative “Improvement Partnership” and the Pharmaceutical Oncology Initiative (POI), a group of pharmaceutical companies who research, develop and supply innovative cancer medicines. The 12 companies which have supported C-PORT are all members of the Association of the British Pharmaceutical Industry (ABPI); Amgen, AstraZeneca , Lilly, Merck Serono, GlaxoSmithKline, Novartis, Ortho Biotech, Pfizer, Roche, Sanofi-Aventis, Schering-Plough and Wyeth. Contact jh&a@holdingassociates.co.uk
A.T. Kearney is a global management consultancy providing strategy and operations consulting to leading companies in many industries, including healthcare. Contact Jonathan.anscombe@atkearney.com
Concentra is a Microsoft Gold Partner with a proven track record in developing, implementing and supporting technology solutions to help clients get the most from their IT investment. www.concentra.co.uk
Itransition is an international software development company featured in Global Outsourcing 100 edition with development centers in Eastern Europe. With the pool of more than 450 software developers in staff Itransition specializes in enterprise level application development for medium size and big business. www.itransition.com
Itransition is an international software development company featured in Global Outsourcing 100 edition with development centers in Eastern Europe. With the pool of more than 450 software developers in staff Itransition specializes in enterprise level application development for medium size and big business.
Itransition
2, Melnikayte St., Minsk, 220004, Belarus
Tel./fax: +375 17 222 61 08
Alexandra Antsugay
a.antsugay@itransition.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Partnership project between the pharmaceutical industry and the NHS recognised as an example of a 'global top 100' IT organisation here
News-ID: 24224 • Views: …
More Releases from Itransition Software
Itransition Named to the Global Outsourcing 100 List for the third time
Itransition, a leading international software development company, was named to the Global Outsourcing 100 list. To enter the list Itransition demonstrated excellence in categories such as size and growth, customer experience, depth and breadth of competencies, and management capabilities.
The Global Outsourcing 100 recognizes the world's best outsourcing service providers (itransition.com) across all industries, and is based on applications evaluated by an independent panel of judges.
The Global Outsourcing 100 is…
Sergey Gvardeitsev, CEO of ITransition, winner of “Man of Business 2008” awa …
Minsk, Belarus – July, 10, 2008 – Sergey Gvardeitsev, CEO of ITransion awarded “Man of Business” prize in the nomination «for establishing an enterprise showing an example of the transition to innovative track of development”.
The “Man of Business” contest is held in Minsk annually with the purpose of revealing twelve most successful top-managers. The decision is based on the business activity of the enterprises that they head. This year’s contest…
Itransition Judged a Finalist in the European IT Excellence Awards
Manchester, UK, Jan. 03, 2008 – Itransition Software was judged a finalist today in the E-business category of the European IT Excellence Awards organized by IT Europa.
The European IT Excellence Awards are the only pan-European awards that recognize best practices in solutions and customer services in the European IT channels and encourage partnerships, convergence and synergy in the IT sphere. The numerous criteria were applied for choosing finalists including…
SoftJournal.ru Has Been Extended by New Rubric SAP
The new rubric dedicated to SAP appears in November issue of SoftJournal.ru. SAP is a commercial software and conceptual complex that suggests a comprehensive approach to enterprise management. The new rubric will describe features of ERP systems, possible ways of their customization with a glance to enterprise needs and other aspects of this area.
«SAP AG is the largest ERP software vendor and one of the biggest software providers in terms…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…